Multiple sclerosis (MS) is more frequent in women at fertile age than in any other age group.
A drug used in the treatment of multiple sclerosis remitting (EMR), which until now was contraindicated in pregnancy, may be administered to pregnant women who suffer from this disease from now on, when a study in which we have analyzed over 8,000 pregnancies over 20 years, has demonstrated its safety for patients and fetuses.
Around 43% of the patients it decided to have a child after the diagnosis of multiple sclerosis
He is the drug COPAXONE® 20 mg/ml, marketed by the pharmaceutical company TEVA announced the modification of your sheet in Spain, so that it can be used in the case of women who need treatment during pregnancy have a very active disease.
Multiple sclerosis (MS) is more frequent in women at fertile age than in any other age group, and it is estimated that around 43% of the patients he decides to have a child after diagnosis. Drug treatment is usually suspended when the affected start planning a pregnancy, or it occurs spontaneously; However, patients with severe or very active EMR are at more risk of disease outbreaks if they leave treatment.
As explained by Rainel Sánchez, Medical Director of TEVA Spain, is preferable to avoid medications during pregnancy whenever possible, but currently, data on the use of COPAXONE® in pregnancy do not indicate neither toxicity nor malformations to the fetus or the newborn, so the drug could be used, provided that the benefit for the mother outweigh the risk for future baby according to medical criteria.